stockportfolio.pro
Stocks / JNJ vs NVS
JNJ vs NVS
Johnson & Johnson and Novartis AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Johnson & Johnson (JNJ) | Novartis AG (NVS) | |
|---|---|---|
| Market cap | $567.3B | $290.6B |
| Revenue (latest FY) | $94.19B | $56.67B |
| Net income (latest FY) | $26.80B | $13.98B |
| Revenue growth (5y CAGR) | 2.7% | 9.3% |
| Net margin | 28.5% | 24.7% |
| Return on equity | 32.9% | 30.3% |
| P/E ratio | 27.9 | 21.8 |
| Dividend yield | 2.2% | 3.2% |
| Profitable years (of last 10) | 10 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open JNJ — free Open NVS — freeFrequently asked questions
Which is bigger, JNJ or NVS?
Johnson & Johnson is larger by market capitalization — $567.3B versus $290.6B.
Which grows faster, JNJ or NVS?
Over the last five fiscal years, Novartis AG grew revenue faster — 9.3%/yr versus 2.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.